A multi-investigator team has received $4 million from NCI to study immunotherapy in diffuse midline glioma.Â
Led by Lyor Cohen, global head of music at YouTube and Google, City of Hope raised more than $4.3 million at its Music, Film and Entertainment Industry fundraising group’s Spirit of Life gala.
Fox Chase Cancer Center has invested in Nucleus RadioPharma, a company specializing in the development and distribution of radiopharmaceuticals, targeted therapies that deliver radiation directly to cancer cells.Â
UCI Health has acquired GenesisCare radiation oncology centers in Orange County.Â
MIB Agents, a pediatric osteosarcoma nonprofit, is accepting applications for its annual OutSmarting Osteosarcoma research grant program. This program was established in 2017 and is awarded to projects focused on moving research forward for osteosarcoma patients.Â
The COVID-19 pandemic was associated with significant changes in diagnoses of all cancer types in 2020, with a 14.4% overall decline in the number of reported cancer cases in cancer centers accredited by the Commission on Cancer (CoC) compared with the prior year.Â
The phase III CheckMate -67T has met its co-primary pharmacokinetics endpoints and a key secondary endpoint of noninferior objective response rate.Â
The phase III MATTERHORN trial showed treatment with Imfinzi (durvalumab) in combination with standard-of-care FLOT neoadjuvant chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel given before surgery) demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of pathologic complete response versus neoadjuvant chemotherapy alone for patients with resectable, early-stage and locally advanced (stages 2, 3, 4A) gastric and gastroesophageal junction cancers.Â
Imfinzi (durvalumab) plus platinum-based chemotherapy, followed by either Imfinzi monotherapy or Imfinzi plus Lynparza (olaparib) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy alone in the overall trial population of patients with newly diagnosed advanced or recurrent endometrial cancer.Â
After 27.7 months of follow-up in the phase III NATALEE trial, the invasive disease-free survival benefit with Kisqali (ribociclib) plus endocrine therapy was consistent across key prespecified subgroups, compared to ET alone, in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC). Â
